About Us Advertise Careers Contact Us Privacy Policy Community Guidelines
Locating… 13°C English WhatsApp Alerts Email Alerts
BREAKING NEWS
EHang completes Sri Lanka’s first human-carrying eVTOL flights - Asian Aviation What’s Happening in Space Policy November 15-21, 2026 Vulcan’s Return-to-Flight Fails How Some News Gets Wings: An Alternative Reading On Viral Footage Of Israeli Tourists In Sri Lanka - OpEd - Eurasia Review Starship Returns to its Launch Pad From Orbit After tracking more than 440 female Asian elephants in Sri Lanka for 12 years, US researchers found that - The Times of India ULA suffers first total mission failure with loss of Vulcan rocket carrying 40 Amazon Leo satellites Sri Lanka records large-scale seasonal butterfly movement — Mongabay - UA.NEWS As butterflies sweep Sri Lanka, global study finds expanding ranges linked to climate change - news - Mongabay APOD: 2026 November 16 – NGC 7129: Star Formation with Jets from Webb
SRI LANKA NEWS

Medical Product Alert N°4/2023: Substandard (contaminated) syrup medicines - World Health Organization (WHO)

Lanka Hit News • Apr 25, 2023 · 3y ago • 2 min read
Share:

This WHO Medical Product Alert refers to a batch of substandard (contaminated) GUAIFENESIN SYRUP TG SYRUP identified in the Marshall Islands and Micronesia (Federated States of) and reported to WHO on 6 April 2023.

Guaifenesin is an expectorant used to relieve chest congestion and the symptoms of cough.

Samples of the GUAIFENESIN SYRUP TG SYRUP from the Marshall Islands were analysed by quality control laboratories of the Therapeutic Goods Administration (TGA) of Australia. The analysis found that the product contained unacceptable amounts of diethylene glycol and ethylene glycol as contaminants.

The stated manufacturer of the affected product is QP PHARMACHEM LTD (Punjab, India). The stated marketer of the product is TRILLIUM PHARMA (Haryana, India). To date, neither the stated manufacturer nor the marketer have provided guarantees to WHO on the safety and quality of these products.

The product referenced in this Alert may have marketing authorizations in other countries in the Western Pacific region. It may have also been distributed, through informal markets, to other countries or regions.

Please refer to the Annex of this Alert for full details of the affected products.

Diethylene glycol and ethylene glycol are toxic to humans when consumed and can prove fatal.

The substandard product referenced in this Alert is unsafe and its use, especially in children, may result in serious injury or death. Toxic effects can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state and acute kidney injury which may lead to death.

If you have the affected product, WHO recommends that you do not use it. If you, or someone you know, has or may have used the affected product, or suffered an adverse reaction or unexpected side-effect after use, you are advised to seek immediate medical advice from a healthcare professional.

WHO requests increased surveillance and diligence within the supply chains of countries and regions likely to be affected by these products. Increased surveillance of the informal/unregulated market is also advised. National regulatory authorities/health authorities are advised to immediately notify WHO if these substandard products are discovered in their respective country.

Manufacturers of liquid dosage forms, especially syrups that contain excipients including propylene glycol, sorbitol, and/or glycerin/glycerol, are urged to test for the presence of contaminants such as ethylene glycol and diethylene glycol before use in medicines.

Healthcare professionals should report any suspicious cases of adverse events linked to the use of these contaminated medicines to the National Regulatory Authorities/ National Pharmacovigilance Centre.

If you have any information about the manufacture or supply of these products, please contact WHO via rapidalert@who.int .

Please see Annex for details of the affected products referenced in Alert N°4/2023.

WHO Global Surveillance and Monitoring System

for Substandard and Falsified Medical Products

For more information, please visit our website

Medical Product Alert N°4/2023: Substandard (contaminated) syrup medicines

Join the Conversation